UTHR
United Therapeutics Corporation
541.90$
+12.5%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.6% | 26.1% | 40.3% | 27.5% | 47.8% | -14.3% | 50.9% | 35.5% | 41.4% | 42.0% | 46.1% | 49.1% | |
| 2.5% | 2.2% | 2.0% | 1.8% | 2.2% | 3.2% | 3.4% | 3.0% | 2.6% | 2.3% | 2.5% | 2.7% | |
| 14.8% | 19.1% | 0.8% | 4.3% | -1.6% | 3.1% | 11.0% | 8.2% | 5.5% | 1.7% | 5.0% | 4.6% | |
| 12.9% | -7.3% | 1.0% | 6.0% | -1.5% | 2.3% | 8.2% | 14.6% | 8.8% | – | – | – | |
| -15.6% | -13.8% | -7.3% | -4.5% | 7.6% | -12.3% | 4.3% | -10.3% | -7.3% | -4.2% | -2.1% | -3.3% | |
| 3.7% | 3.4% | 2.7% | 5.0% | 11.3% | 5.8% | 4.0% | 7.2% | 7.2% | 9.9% | 8.6% | 16.4% | |
| 26.3% | 34.4% | 3.0% | -48.4% | -50.4% | -23.2% | -49.8% | -28.9% | -41.9% | -30.9% | 14.5% | -17.3% | |
| 14.8% | 2.7% | 0.5% | 0.0% | – | 1.0% | 2.6% | – | 4.9% | 4.2% | – | – | |
| -37.5% | -26.9% | -31.3% | -14.5% | 1.2% | -0.1% | -0.2% | -0.6% | -0.6% | -0.6% | -35.2% | -31.4% | |
| -13.8% | -9.1% | -1.0% | 14.4% | -0.8% | 41.4% | -3.5% | 0.0% | -0.4% | -4.3% | -13.9% | -9.4% | |
| -44.7% | -30.5% | -31.1% | 2.5% | 0.4% | 42.2% | -1.1% | 2.7% | 3.9% | -0.5% | -43.6% | -36.1% | |
| 8.8% | 29.6% | 12.0% | -18.4% | -2.2% | 4.8% | 0.0% | 9.3% | 3.4% | 10.6% | 17.0% | -4.4% | |
| 23.9% | 22.7% | 37.6% | 22.5% | 36.5% | -20.0% | 46.9% | 28.3% | 34.3% | 32.1% | 37.6% | 32.7% |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.